How long does it take for Lorlatinib to take effect? Clinical trial data and patient feedback

Lorlatinib (Lolatinib) is a third-generation ALK/ROS1tyrosine kinase inhibitor, mainly used to treat ALKPatients with positive non-small cell lung cancer (NSCLC), especially those who have developed resistance or disease progression to previous generation ALK inhibitors (such as crizotinib, alectinib, etc.). Lorlatinib (Lorlatinib) is unique in its strong brain penetration ability and has good curative effect on lung cancer patients with brain metastasis.

According to clinical trial data, the efficacy of lorlatinib in patients with ALK-positive non-small cell lung cancer typically takes weeks to months to develop. Early clinical data suggests that patients typically experience significant reductions in tumor burden and decreases in tumor markers such as C-reaction protein (CRP) within approximately 6 weeks of treatment. However, a complete efficacy evaluation usually takes more than 6 months, especially when treated with lorlatinib (lorlatinib). The shrinkage of brain metastases is usually slower, so in patients with brain metastases, the observation period for treatment effects may need to be extended.

Data from a pivotal clinicalIII trial (CROWN trial) show thatlorlatinib (lorlatinib) has an objective response rate ( pan>ORR) reached 76%, and had a significant progression-free survival (PFS) advantage. Compared with other first-line ALK inhibitors, lorlatinib (lorlatinib) showed stronger efficacy in patients with brain metastases. In this trial, after most patients received lorlatinib (lorlatinib) treatment, the tumor shrinking effect began to appear within 4-6 weeks and lasted for a long time, and some patients were able to maintain long-term remission.

Judging from patient feedback, the efficacy of lorlatinib (lorlatinib) varies among different patient groups, but most patients can feel an improvement in symptoms after a few weeks, especially the relief of pulmonary symptoms such as dyspnea and cough. In addition, lorlatinib (lorlatinib) is particularly effective in patients with brain metastases. Many patients reported that symptoms related to brain metastases such as headaches and blurred vision were significantly improved after treatment. Despite this, some patients experience more obvious side effects in the early stages, such as high cholesterol, high blood sugar, fatigue, etc., but overall, the severity of side effects usually decreases as treatment continues.

Reference link:https://www.lorbrena.com/